These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8911877)

  • 41. Positive inotropic and hemodynamic properties of flosequinan, a new vasodilator, and a sulfone metabolite.
    Falotico R; Haertlein BJ; Lakas-Weiss CS; Salata JJ; Tobia AJ
    J Cardiovasc Pharmacol; 1989 Sep; 14(3):412-8. PubMed ID: 2476620
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The flosequinan experience and its implications.
    Hingorani AD
    Br J Hosp Med; 1993 Dec 15-1994 Jan 18; 50(11):683; author reply 683-4. PubMed ID: 8124556
    [No Abstract]   [Full Text] [Related]  

  • 43. Flosequinan: a new vasodilator for the treatment of heart failure.
    Dutka DP; Cleland JG
    Br J Hosp Med; 1993 May 5-18; 49(9):654-5. PubMed ID: 8508260
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure.
    Krum H; Sackner-Bernstein JD; Goldsmith RL; Kukin ML; Schwartz B; Penn J; Medina N; Yushak M; Horn E; Katz SD
    Circulation; 1995 Sep; 92(6):1499-506. PubMed ID: 7664433
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Exercise tolerance in patients with heart failure--how should it be measured?
    Cowley AJ; Fullwood L; Stainer K; Hampton JR
    Eur Heart J; 1991 Jan; 12(1):50-4. PubMed ID: 2009893
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Relation of circulating cardiac myosin light chain 1 isoform in stable severe congestive heart failure to survival and treatment with flosequinan.
    Hansen MS; Stanton EB; Gawad Y; Packer M; Pitt B; Swedberg K; Rouleau JL;
    Am J Cardiol; 2002 Nov; 90(9):969-73. PubMed ID: 12398964
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study.
    Packer M; Gheorghiade M; Young JB; Costantini PJ; Adams KF; Cody RJ; Smith LK; Van Voorhees L; Gourley LA; Jolly MK
    N Engl J Med; 1993 Jul; 329(1):1-7. PubMed ID: 8505940
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Flosequinan: a vasodilator with positive inotropic activity.
    Corin WJ; Monrad ES; Strom JA; Giustino S; Sonnenblick ES; LeJemtel T
    Am Heart J; 1991 Feb; 121(2 Pt 1):537-40. PubMed ID: 1990760
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of concurrent administration of flosequinan and digoxin on the pharmacokinetics of each drug.
    Rau R; Hind ID; Wynne RD; White SA
    Arzneimittelforschung; 1994 Mar; 44(3):300-4. PubMed ID: 8192694
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Heart failure: drug therapy in the nineties and beyond.
    Conti CR
    Clin Cardiol; 1993 Jun; 16(6):459-60. PubMed ID: 8358878
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pulmonary Vascular Distensibility Predicts Pulmonary Hypertension Severity, Exercise Capacity, and Survival in Heart Failure.
    Malhotra R; Dhakal BP; Eisman AS; Pappagianopoulos PP; Dress A; Weiner RB; Baggish AL; Semigran MJ; Lewis GD
    Circ Heart Fail; 2016 Jun; 9(6):. PubMed ID: 27301469
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Addition of candesartan to angiotensin converting enzyme inhibitor therapy in patients with chronic heart failure does not reduce levels of oxidative stress.
    Ellis GR; Nightingale AK; Blackman DJ; Anderson RA; Mumford C; Timmins G; Lang D; Jackson SK; Penney MD; Lewis MJ; Frenneaux MP; Morris-Thurgood J
    Eur J Heart Fail; 2002 Mar; 4(2):193-9. PubMed ID: 11959049
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Assessing the treatment of congestive heart failure: diuretics, vasodilators, and angiotensin-converting enzyme inhibitors.
    Chow MS
    Pharmacotherapy; 1993; 13(5 Pt 2):82S-87S. PubMed ID: 8233997
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chronic ACE inhibition enhances the endothelial control of arterial mechanics and flow-dependent vasodilatation in heart failure.
    Joannides R; Bizet-Nafeh C; Costentin A; Iacob M; Derumeaux G; Cribier A; Thuillez C
    Hypertension; 2001 Dec; 38(6):1446-50. PubMed ID: 11751733
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Flosequinan for heart failure.
    Med Lett Drugs Ther; 1993 Mar; 35(892):23-4. PubMed ID: 8441362
    [No Abstract]   [Full Text] [Related]  

  • 56. Effects of balanced vasodilator, flosequinan, on aortic impedance in failing heart.
    Yano M; Kohno M; Yamamoto T; Hisaoka T; Tanigawa T; Ono K; Lee B; Konishi M; Matsuzaki M
    J Cardiovasc Pharmacol; 1998 Sep; 32(3):466-70. PubMed ID: 9733361
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Disparate results of ACE inhibitor dosage on exercise capacity in heart failure: a reappraisal of vasodilator therapy and study design.
    Williams SG; Cooke GA; Wright DJ; Tan LB
    Int J Cardiol; 2001 Feb; 77(2-3):239-45. PubMed ID: 11182188
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Duration and reproducibility of initial hemodynamic effects of flosequinan in patients with congestive heart failure.
    Bartels GL; Remme WJ; Wiesfeld AC; Kok FJ; Look MP; Krauss XH; Kruyssen HA
    Cardiovasc Drugs Ther; 1990 Jun; 4(3):705-12. PubMed ID: 2076381
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and safety of flosequinan, given over 3 days, evaluated by continuous hemodynamic monitoring.
    Schneeweiss A; Plich M; Green T; Wynne RD; Marmor A
    Cardiology; 1989; 76(3):201-5. PubMed ID: 2776141
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of flosequinan (BTS 49465) on myocardial oxygen consumption.
    Greenberg S; Touhey B; Paul J
    Am Heart J; 1990 Jun; 119(6):1355-66. PubMed ID: 2353621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.